Condition: Diffuse Large B Cell Lymphoma · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR rate),progression free survival (PFS), duration of response (DOR) and overall survival(OS). The safety evaluation indicators are dose-limiting toxicity (DLT) , maximum tolerated dose (MTD)and recommended phase II dose (RP2D).
This description comes directly from the study's public registry record.
Yuqin Song, Doctor · 13683398726 · SongYQ_VIP@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | Not Yet Recruiting |
| Maanshan People's Hospital | Ma’anshan, Anhui, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Fujian Medical University | Quanzhou, Fujian, China | Recruiting |
| Gansu Provincial Cancer Hospital | Lanzhou, Gansu, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Liuzhou People's Hospital | Liuzhou, Guangxi, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Puyang Oilfield General Hospital | Puyang, Henan, China | Not Yet Recruiting |
| Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Not Yet Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06829771